• Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
  • Facebook
  • LinkedIn
  • Twitter
  • Vimeo
Home
Research areas
    ADME-Tox
    Biomarkers
    Cell Biology and Signalling
    Cell Sourcing - Cell Culture Technologies
    Drug Discovery
    Gene Expression - Molecular Biology
    Stem Cells
    Supplying Discovery Tools
Contact us
Meet the authors
Tebubio's blog - Acting and reacting in life sciences and biotechnologies
  • Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
Supplying Discovery Tools

Biotherapies, biosimilars, biobetters… biowhat?

28/07/2014 by Ana Arraztio No Comments

Let’s go step by step.

Biologics (or protein therapeutics, or biotherapies) started as far back as the 1920’s, with the first proteins of animal origin (e.g. porcine/bovine insulin). The first recombinant proteins (i.e. done in the laboratory) were released in the 1980’s. The late XXth and early XXIst century have seen the development of therapeutic monoclonal antibodies (mAbs) to treat different diseases (e.g. cancer). Back in 2009, estimations indicated that the biotherapies market for cancer only could reach up to $60 billion by 2019 (1). Biotherapies represent about half of the total cancer treatment market nowadays.

As one can imagine, this trend towards using more and more biotherapies rather than new chemical entities to treat some complex diseases, has attracted the interest of private and academic research laboratories, as biotherapies really work, and some of them very well (both from the health perspective as well as the marketing one).
It has to be noted, though, that sometimes it can be tricky to get biotherapies approved by National Health & Regulatory bodies, as these therapies are not cheap. The Pharmaceutical Price and Reimbursement Scheme (PPRS) in Europe may limit the access of some patient groups to these new biotherapies in some cases (3). But that’s another story.

Continue reading

Most popular posts

  • HeLa cells: Origin of this important cell line in life science research
  • From RUO to IVD - the acronym guide to reagents' intended use
  • How to choose the perfect buffer to get a pure, stabilised, functional protein
My Tweets

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Copyright © 2018 - tebu-bio - visit our main website at tebu-bio.com